Overview

Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antipsychotic Agents
Haloperidol
Haloperidol decanoate
Olanzapine